Alzheimer's research $45 million boost: Funded by the National Institute of Health (NIH), this disease gets a large chunk of money to help potentially find a cure.

The $45 million boost in research is for what is known as the most common form of dementia. Alzheimer's worsens as it progresses and eventually leads to death.

Just like that, your memory quickly leaves your mind forever. The research of $45 million boost for Alzheimer's is help for one day keeping your memory instead of losing it, not knowing anything from your past, the people you know and love or potentially even yourself.

The studies all reflect research goals in the National Plan to Address Alzheimer's Disease External Web Site Policy. Of the funding, $40 million is from an allocation from the Office of the NIH Director, Dr. Francis Collins, with additional funding from the National Institute on Aging (NIA), the lead Institute within NIH for Alzheimer's research.

"As many as 5 million Americans face the challenge of Alzheimer's disease, which robs them of their memories, their independence and ultimately, their lives," Collins said in a statement. "We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer's biology and find effective therapies as quickly as possible."

One of the projects that the funding will support is the Alzheimer's Prevention Initiative APOE4 Trial with the Banner Alzheimer's Institute, according to USA Today. This five-year trial will test an anti-amyloid drug in cognitively healthy adults, ages 60-75, which are at increased risk of developing late-onset Alzheimer's. They inherited two copies of the APOE4 allele, a major genetic risk factor.

"Once again, we are extremely grateful to the NIH for the opportunity to help accelerate the evaluation of treatments to prevent the clinical onset of Alzheimer's and find ones that work as soon as possible," said Eric Reiman, executive director of the Banner Alzheimer's Institute, in a statement. "This trial will allow us to extend our work to individuals at greatest risk at older ages."

With people living longer, this means dementia will increase in numbers.